Gloucester Pharmaceuticals Strengthens Management Team in Key Areas.

CAMBRIDGE, Mass. -- Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that it has expanded its management team with the addition of two senior directors in newly created positions. Mitchell Keegan, Ph.D. joins the company as Senior Director, Drug Development and Brian Wiley joins as Senior Director, Marketing and Business Planning.

Dr. Keegan is an accomplished pharmacologist with ten years of progressive research and organizational leadership experience. Most recently, he was Director of Pharmacology at CombinatoRx, Inc., where he directed the company's pharmacology department and participated on development teams for products in the areas of oncology, diabetes and inflammation. Prior to that, he managed the genetic toxicology department at Toxikon Corporation, and was a research fellow at the Harvard Medical School/Joslin Diabetes Center. Dr. Keegan received a BS from the University of Sydney in Australia and his PhD in molecular and cellular biology from the University of Western Sydney in Australia.

Mr. Wiley brings to Gloucester over ten years of commercial oncology experience with a variety of products including Taxotere(R), Velcade(R), Oncaspar(R), Gliadel Wafer(R) and Anzemet(R). He joins Gloucester from Millennium Pharmaceuticals, where he served as Associate Director, Market Planning and Development and focused on strategic and pre-market planning for Velcade in emerging indications. Mr. Wiley's previous experience includes a diverse 12 year tenure at Aventis Pharmaceuticals (now Sanofi-Aventis), including management positions in marketing, national accounts & sales. In his most recent position as Senior Manager, Oncology Networks he developed and implemented contracting strategies for $700 million in annual oncology product sales for Taxotere, and Anzemet. He was also instrumental in the successful launch of Taxotere in the non-small cell lung cancer (NSCLC) market. Mr. Wiley received a BS from The Pennsylvania State University and completed graduate level coursework at the University of New Mexico.

"We are pleased to have Mitch and Brian join our expanding team at Gloucester," said Joseph S. "Jay" Mohr, President and CEO of Gloucester. "Their respective experience in oncology drug development, sales and marketing will be invaluable as depsipeptide continues to make progress in a pivotal clinical trial of patients with cutaneous T-cell lymphoma as well as other studies for hematologic and solid tumor indications."

About Depsipeptide

Depsipeptide is one of a new class of anti-cancer agents, known as histone deacetylase inhibitors. Depsipeptide was granted Fast Track and Orphan Drug designations by the Food and Drug Administration and European Orphan Drug designation by the EMEA as a monotherapy for the treatment of cutaneous T-cell lymphoma in patients who have relapsed following, or become refractory to, one other systemic therapy. It is currently being evaluated in a pivotal clinical trial for this indication. Depsipeptide is also being studied in a range of hematologic and solid tumor indications including hormone refractory prostate cancer in clinical trials sponsored by Gloucester, as well as the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA).

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately held, venture-backed company that develops and commercializes innovative products for the treatment of cancer. The company employs an in-licensing strategy to build a diversified product portfolio to address the significant unmet medical need in the management of cancer. Gloucester's first product is depsipeptide, a novel HDAC inhibitor and is headquartered in Cambridge, MA.

For more information visit our website at www.gloucesterpharma.com.

Taxotere(R), Anzemet(R) are trademarks of Sanofi-Aventis Pharmaceuticals, Inc.

Velcade(R) is a trademark of Millennium Pharmaceuticals, Inc.

Oncaspar(R) is a trademark of Enzon Pharmaceuticals.

Gliadel Wafer(R) is a trademark of Guilford Pharmaceuticals.

This press release contains forward-looking statements concerning Gloucester that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Gloucester's actual results to differ materially from those indicated by such forward-looking statements, including risks as to whether results obtained in pre-clinical and early clinical studies such as the results referred to in this release will be indicative of results obtained in future clinical trials; whether depsipeptide will advance through the clinical trial process and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies and for which indications, if any; and whether the patent and patent applications owned or licensed by Gloucester will protect the Company's technology and prevent others from infringing it. Gloucester disclaims any intention or obligation to update any forward-looking statements.